Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2016 Jun 1.

Published in final edited form as: Endocr Relat Cancer. 2015 Mar 10;22(3):369–386. doi: 10.1530/ERC-15-0021

(A) Formalin fixed paraffin-embedded human localized prostate cancer specimens obtained by prostatectomy were arranged in a tissue microarray and stained with anti-Nrdp1 antibody. Nrdp1 expression (brown staining) was observed in the nucleus, cytoplasm or both and was scored on a 0 to 3 scale in both benign and cancerous prostate tissues. Shown are typical staining from a benign section (score 1) (left) and a section showing Gleason grade 3 tumor (score 3) (right) bar=20µm. (B) Boxplot depicting the distribution of Nrdp1 in the nucleus or cytoplasm of tumor compared to non-tumor tissue (n=78) demonstrate that the expression of nuclear Nrdp1 remains the same in both cancer and non-tumor tissues, whereas cytoplasmic expression of Nrdp1 increases in tumor compared to non-tumor tissue. (C) Nuclear Nrdp1 levels differed significantly by clinical stage (p < 0.001), with post-hoc testing showing significantly higher expression in Stage 2 (T2) and Stage 3 (T3) patients than in Stage 1 (T1) patients (p = 0.001). (D) (left) Boxplots showing the correlation between Nrdp1 and AR in tumor tissue (p<0.001). (right) IHC of AR and Nrdp1 in two patients with high and low AR vs Nrdp1. Note that the patient who expressed little AR also expressed little Nrdp1, whereas strong AR staining correlated with strong Nrdp1 expression. Bar=50µm.

(A) Formalin fixed paraffin-embedded human localized prostate cancer specimens obtained by prostatectomy were arranged in a tissue microarray and stained with anti-Nrdp1 antibody. Nrdp1 expression (brown staining) was observed in the nucleus, cytoplasm or both and was scored on a 0 to 3 scale in both benign and cancerous prostate tissues. Shown are typical staining from a benign section (score 1) (left) and a section showing Gleason grade 3 tumor (score 3) (right) bar=20µm. (B) Boxplot depicting the distribution of Nrdp1 in the nucleus or cytoplasm of tumor compared to non-tumor tissue (n=78) demonstrate that the expression of nuclear Nrdp1 remains the same in both cancer and non-tumor tissues, whereas cytoplasmic expression of Nrdp1 increases in tumor compared to non-tumor tissue. (C) Nuclear Nrdp1 levels differed significantly by clinical stage (p < 0.001), with post-hoc testing showing significantly higher expression in Stage 2 (T2) and Stage 3 (T3) patients than in Stage 1 (T1) patients (p = 0.001). (D) (left) Boxplots showing the correlation between Nrdp1 and AR in tumor tissue (p<0.001). (right) IHC of AR and Nrdp1 in two patients with high and low AR vs Nrdp1. Note that the patient who expressed little AR also expressed little Nrdp1, whereas strong AR staining correlated with strong Nrdp1 expression. Bar=50µm.